论文部分内容阅读
本文报告HBsAg及HBeAg阳性孕妇婴儿于出生时及出生后1个月.6个月,应用乙肝基因疫苗(30例)、乙肝血源疫苗(13例)和乙肝血源疫苗加乙肝高效价免疫球蛋白(HBIG)(14例),在应用后1、2、6、7、9个月时测HBsAg及抗-HBs。从抗-HBs阳转来看,基因疫苗出现早而高,血源疫苗加HBIG次之,单纯应用血源疫苗者最迟,其保护率分别为:100%、85.72%及38.49%。本文又对33例应用乙肝血源疫苗加HBIG儿童于用后9、12、18、24、36个月及6岁时(15例),随访测HBsAg和抗-HBs,结果3岁时HBsAg阳性率18.18%,6岁时为26.67%,而抗-HBs阳性率于9个月时达高峰,以后则渐降,至3岁时仅33.33%,6岁时为26.67%,所以建议6岁前应作加强注射,同时应预防水平传播的可能。
This article reports HBsAg and HBeAg positive pregnant women infants at birth and 1 month after birth 6 months, application of hepatitis B gene vaccine (30 cases), hepatitis B blood vaccine (13 cases) and hepatitis B blood vaccine plus hepatitis B high titer immunoglobulin (HBIG) (14 cases). HBsAg and anti-HBs were measured at 1, 2, 6, 7 and 9 months after application. From the anti-HBs positive point of view, the gene vaccine appeared early but high, followed by blood-borne vaccine and HBIG, the simple application of blood-borne vaccine was the latest, the protection rates were: 100%, 85.72% and 38.49%. In this paper, HBsAg and anti-HBs were also measured in 33 cases of hepatitis B vaccine and HBIG at 9, 12, 18, 24, 36 months and 6 years old (15 cases) The rate was 18.18%, 26.67% at 6 years old, while the positive rate of anti-HBs reached its peak at 9 months, then decreased gradually, reaching 33.33% at 3 years old and 26.67% at 6 years old, Should be enhanced injection, at the same time should prevent the possibility of horizontal transmission.